Free Trial
NASDAQ:CHGA

Avalon GloboCare Q3 2025 Earnings Results & Report

Avalon GloboCare logo
$2.02 +0.01 (+0.50%)
As of 10/9/2026 04:00 PM Eastern

Avalon GloboCare reported Q3 2025 earnings on November 14, 2025. The company reported EPS of -$1.20, while revenue was $0.35 million.

Earnings Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call
7:00 AM ET

Avalon GloboCare EPS Results

Actual EPS
-$1.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Avalon GloboCare Revenue Results

Actual Revenue
$0.35 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Avalon GloboCare Q3 2025 Earnings FAQ

Avalon GloboCare (NASDAQ:CHGA) reported earnings of -$1.20 per share for Q3 2025. The report was announced on Friday, November 14, 2025.

Avalon GloboCare reported revenue of $0.35 million for Q3 2025.

Avalon GloboCare Earnings Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More Avalon GloboCare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avalon GloboCare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalon GloboCare and other key companies, straight to your email.

About Avalon GloboCare

Avalon GloboCare (NASDAQ:CHGA) is a biotechnology company focused on developing cell-based and regenerative medicine technologies. Its work has included cellular immunotherapies, exosome-based products and other platforms intended to support the treatment of cancer and other serious medical conditions.

The company has also pursued activities involving cell and gene therapy development, biobanking and related laboratory services. Avalon GloboCare has described its business as spanning research, product development and potential commercialization through collaborations and strategic partnerships.

Avalon GloboCare was founded in the United States and has historically been associated with operations in New Jersey. Publicly available company materials have identified David Jin as a senior executive, although the company’s operating status, leadership and securities information may have changed. Avalon GloboCare has historically traded under the symbol AVCO; the symbol provided, CHGA, could not be independently confirmed as its current listing.

View Avalon GloboCare Profile